1
|
Singh A, Kinnebrew G, Hsu PC, Weng DY, Song MA, Reisinger SA, McElroy JP, Keller-Hamilton B, Ferketich AK, Freudenheim JL, Shields PG. Untargeted Metabolomics and Body Mass in Adolescents: A Cross-Sectional and Longitudinal Analysis. Metabolites 2023; 13:899. [PMID: 37623843 PMCID: PMC10456720 DOI: 10.3390/metabo13080899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 07/25/2023] [Accepted: 07/27/2023] [Indexed: 08/26/2023] Open
Abstract
Obesity in children and adolescents has increased globally. Increased body mass index (BMI) during adolescence carries significant long-term adverse health outcomes, including chronic diseases such as cardiovascular disease, stroke, diabetes, and cancer. Little is known about the metabolic consequences of changes in BMI in adolescents outside of typical clinical parameters. Here, we used untargeted metabolomics to assess changing BMI in male adolescents. Untargeted metabolomic profiling was performed on urine samples from 360 adolescents using UPLC-QTOF-MS. The study includes a baseline of 235 subjects in a discovery set and 125 subjects in a validation set. Of them, a follow-up of 81 subjects (1 year later) as a replication set was studied. Linear regression analysis models were used to estimate the associations of metabolic features with BMI z-score in the discovery and validation sets, after adjusting for age, race, and total energy intake (kcal) at false-discovery-rate correction (FDR) ≤ 0.1. We identified 221 and 16 significant metabolic features in the discovery and in the validation set, respectively. The metabolites associated with BMI z-score in validation sets are glycylproline, citrulline, 4-vinylsyringol, 3'-sialyllactose, estrone sulfate, carnosine, formiminoglutamic acid, 4-hydroxyproline, hydroxyprolyl-asparagine, 2-hexenoylcarnitine, L-glutamine, inosine, N-(2-Hydroxyphenyl) acetamide glucuronide, and galactosylhydroxylysine. Of those 16 features, 9 significant metabolic features were associated with a positive change in BMI in the replication set 1 year later. Histidine and arginine metabolism were the most affected metabolic pathways. Our findings suggest that obesity and its metabolic outcomes in the urine metabolome of children are linked to altered amino acids, lipid, and carbohydrate metabolism. These identified metabolites may serve as biomarkers and aid in the investigation of obesity's underlying pathological mechanisms. Whether these features are associated with the development of obesity, or a consequence of changing BMI, requires further study.
Collapse
Affiliation(s)
- Amarnath Singh
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210-1240, USA; (A.S.); (D.Y.W.)
| | - Garrett Kinnebrew
- Department of Biomedical Informatics, Biomedical Informatics Shared Resources (BISR), The Ohio State University, Columbus, OH 43210-1240, USA;
| | - Ping-Ching Hsu
- Department of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA;
| | - Daniel Y. Weng
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210-1240, USA; (A.S.); (D.Y.W.)
| | - Min-Ae Song
- College of Public Health, The Ohio State University, Columbus, OH 43210-1240, USA; (M.-A.S.); (A.K.F.)
| | - Sarah A. Reisinger
- Center for Tobacco Research, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210-1240, USA; (S.A.R.); (B.K.-H.)
| | - Joseph P. McElroy
- Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210-1240, USA;
| | - Brittney Keller-Hamilton
- Center for Tobacco Research, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210-1240, USA; (S.A.R.); (B.K.-H.)
- Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210-1240, USA
| | - Amy K. Ferketich
- College of Public Health, The Ohio State University, Columbus, OH 43210-1240, USA; (M.-A.S.); (A.K.F.)
| | - Jo L. Freudenheim
- Department of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY 14214, USA;
| | - Peter G. Shields
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210-1240, USA; (A.S.); (D.Y.W.)
| |
Collapse
|
2
|
Ogilvie CE, Czekster CM. Cyclic dipeptides and the human microbiome: Opportunities and challenges. Bioorg Med Chem 2023; 90:117372. [PMID: 37343497 DOI: 10.1016/j.bmc.2023.117372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2023] [Revised: 05/24/2023] [Accepted: 06/07/2023] [Indexed: 06/23/2023]
Abstract
Research into the human microbiome has implicated its constituents in a variety of non-communicable diseases, with certain microbes found to promote health and others leading to dysbiosis and pathogenesis.Microbes communicate and coordinate their behaviour through the secretion of small molecules, such as cyclic dipeptides (CDPs), into their surrounding environment. CDPs are ubiquitous signalling molecules thatexhibit a wide range of biological activities, with particular relevance to human health due to their potential to act as microbiome modulators.
Collapse
Affiliation(s)
- Charlene Elizabeth Ogilvie
- School of Biology, Biomedical Sciences Research Complex, University of St Andrews, St Andrews, Fife KY16 9ST, United Kingdom.
| | - Clarissa Melo Czekster
- School of Biology, Biomedical Sciences Research Complex, University of St Andrews, St Andrews, Fife KY16 9ST, United Kingdom.
| |
Collapse
|
3
|
Guan J, Li F, Kang D, Anderson T, Pitcher T, Dalrymple-Alford J, Shorten P, Singh-Mallah G. Cyclic Glycine-Proline (cGP) Normalises Insulin-Like Growth Factor-1 (IGF-1) Function: Clinical Significance in the Ageing Brain and in Age-Related Neurological Conditions. Molecules 2023; 28:molecules28031021. [PMID: 36770687 PMCID: PMC9919809 DOI: 10.3390/molecules28031021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Revised: 01/16/2023] [Accepted: 01/17/2023] [Indexed: 01/20/2023] Open
Abstract
Insulin-like growth factor-1 (IGF-1) function declines with age and is associated with brain ageing and the progression of age-related neurological conditions. The reversible binding of IGF-1 to IGF binding protein (IGFBP)-3 regulates the amount of bioavailable, functional IGF-1 in circulation. Cyclic glycine-proline (cGP), a metabolite from the binding site of IGF-1, retains its affinity for IGFBP-3 and competes against IGF-1 for IGFBP-3 binding. Thus, cGP and IGFBP-3 collectively regulate the bioavailability of IGF-1. The molar ratio of cGP/IGF-1 represents the amount of bioavailable and functional IGF-1 in circulation. The cGP/IGF-1 molar ratio is low in patients with age-related conditions, including hypertension, stroke, and neurological disorders with cognitive impairment. Stroke patients with a higher cGP/IGF-1 molar ratio have more favourable clinical outcomes. The elderly with more cGP have better memory retention. An increase in the cGP/IGF-1 molar ratio with age is associated with normal cognition, whereas a decrease in this ratio with age is associated with dementia in Parkinson disease. In addition, cGP administration reduces systolic blood pressure, improves memory, and aids in stroke recovery. These clinical and experimental observations demonstrate the role of cGP in regulating IGF-1 function and its potential clinical applications in age-related brain diseases as a plasma biomarker for-and an intervention to improve-IGF-1 function.
Collapse
Affiliation(s)
- Jian Guan
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine and Health Sciences, School of Biomedical Sciences, The University of Auckland, Auckland 1142, New Zealand
- Centre for Brain Research, Faculty of Medicine and Health Sciences, School of Biomedical Sciences, The University of Auckland, Auckland 1142, New Zealand
- Brain Research New Zealand, The Centre for Research Excellent, Dunedin 9016, New Zealand
- The cGP Lab Limited New Zealand, Auckland 1021, New Zealand
- Correspondence: ; Tel.: +64-9-923-6134
| | - Fengxia Li
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine and Health Sciences, School of Biomedical Sciences, The University of Auckland, Auckland 1142, New Zealand
- Centre for Brain Research, Faculty of Medicine and Health Sciences, School of Biomedical Sciences, The University of Auckland, Auckland 1142, New Zealand
- Guangdong Pharmaceutical University, Guangzhou Higher Education Mega Center, Guangzhou 510075, China
- The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China
| | - Dali Kang
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine and Health Sciences, School of Biomedical Sciences, The University of Auckland, Auckland 1142, New Zealand
- Centre for Brain Research, Faculty of Medicine and Health Sciences, School of Biomedical Sciences, The University of Auckland, Auckland 1142, New Zealand
- Brain Research New Zealand, The Centre for Research Excellent, Dunedin 9016, New Zealand
- Shenyang Medical College, Shenyang 110034, China
| | - Tim Anderson
- New Zealand Brain Research Institute, Christchurch 4710, New Zealand
- Department of Medicine, University of Otago, Dunedin 9016, New Zealand
- Department of Neurology, Canterbury District Health Board, Christchurch 4710, New Zealand
| | - Toni Pitcher
- New Zealand Brain Research Institute, Christchurch 4710, New Zealand
- Department of Medicine, University of Otago, Dunedin 9016, New Zealand
- Department of Neurology, Canterbury District Health Board, Christchurch 4710, New Zealand
| | - John Dalrymple-Alford
- Department of Neurology, Canterbury District Health Board, Christchurch 4710, New Zealand
- Department of Psychology, University of Canterbury, Christchurch 4710, New Zealand
| | - Paul Shorten
- AgResearch Ltd., Ruakura Research Centre, Hamilton 3214, New Zealand
- Riddet Institute, Massey University, Palmerston North 4474, New Zealand
| | - Gagandeep Singh-Mallah
- Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden
| |
Collapse
|
4
|
Abdullina AA, Vasileva EV, Kulikova EA, Naumenko VS, Plyusnina AV, Gudasheva TA, Kovalev GI, Seredenin SB. The neuropeptide cycloprolylglycine produces antidepressant-like effect and enhances BDNF gene expression in the mice cortex. J Psychopharmacol 2022; 36:214-222. [PMID: 35102783 DOI: 10.1177/02698811211069101] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Cycloprolylglycine (CPG) is an endogenous dipeptide with a wide range of psychotropic activity and putative therapeutic potential for depression. A small but growing body of data suggests that antidepressant-like effect of CPG is associated with neuroplastic changes in the brain or 5-HT system modulation. However, the mechanisms of the dipeptide action remain elusive. AIMS Here, we characterize the effects of chronic CPG administration on behavior and genes expression of antidepressants sensitive catalepsy (ASC) mice strain, characterized by depressive-like behavior. METHODS ASC mice were injected with saline, fluoxetine (10 mg/kg/day), or CPG (1 and 2 mg/kg/day) during 2 weeks. Behavior was studied using the open field test, novel object test, elevated plus maze test, forced swim test, and tail suspension test (TST). The expressions of genes coding BDNF, CREB, 5-HT1A and 5-HT2A receptors, TPH2, and SERT in the brain were measured with quantitative real-time reverse transcription polymerase chain reaction (RT-PCR). RESULTS Chronic intraperitoneal administration of 1 and 2 mg/kg of CPG revealed the significant antidepressant-like effect by decreasing immobility time in the TST. At the same time, CPG did not negatively affect locomotor activity, cognition, or anxiety. In the real-time quantitative polymerase chain reaction (PCR) assay, chronic CPG treatment (2 mg/kg for 14 days) increased Bdnf mRNA level in the frontal cortex. CONCLUSIONS Our findings extend the evidence for the effectiveness of CPG to reduce depressive-like behaviors. The antidepressant-like effect of CPG is mediated, as least in part, by BDNF-dependent mechanism. The exact mechanism remains to be elucidated, and further studies are warranted.
Collapse
Affiliation(s)
| | | | - Elizabeth A Kulikova
- Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russia
| | - Vladimir S Naumenko
- Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russia
| | - Alexandra V Plyusnina
- Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russia
| | | | | | | |
Collapse
|
5
|
Kaneko H, Namihira M, Yamamoto S, Numata N, Hyodo K. Oral administration of cyclic glycyl-proline facilitates task learning in a rat stroke model. Behav Brain Res 2022; 417:113561. [PMID: 34509530 DOI: 10.1016/j.bbr.2021.113561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 08/29/2021] [Accepted: 09/01/2021] [Indexed: 11/25/2022]
Abstract
Cyclic glycyl-proline (cGP) exerts neuroprotective effects against ischemic stroke and may promote neural plasticity or network remodeling. We sought to determine to what extent oral administration of cGP could facilitate task learning in rats with ischemic lesions. We trained rats to perform a choice reaction time task using their forepaws. One week after changing the food to pellets containing cGP (no cGP: 0 mg/kg; low cGP: 25 mg/kg; and high cGP: 75 mg/kg), we made a focal ischemic lesion on the left or right forepaw area of the sensorimotor cortex. After recovery of task performance, we altered the correct-response side of the task, and then analyzed the number of training days required for the rat to reach a learning criterion (error rate < 15%) and the regulation of adult neurogenesis in the subventricular zones (SVZs), taking lesion size into account. The low-cGP group required fewer training days for task learning than the no-cGP group. Unexpectedly, rats with larger lesions required fewer training days in the no-cGP and low-cGP groups, but more training days in the high-cGP group. The number of Ki67-immunopositive cells (indicating proliferative cells) in ipsilesional SVZ increased more rapidly in the low-cGP and high-cGP groups than in the no-cGP group. However, lesion size had only a small effect on required training days and the number of Ki67-immunopositive cells. We conclude that oral administration of cGP can facilitate task learning in rats with focal ischemic infarction through neural plasticity and network remodeling, even with minimal neuroprotective effects.
Collapse
Affiliation(s)
- Hidekazu Kaneko
- National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan.
| | - Masakazu Namihira
- National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan
| | | | | | - Koji Hyodo
- National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan
| |
Collapse
|
6
|
Singh-Mallah G, Ardalan M, Kang D, Singh K, McMahon CD, Mallard C, Guan J. Administration of cyclic glycine-proline during infancy improves adult spatial memory, astrocyte plasticity, vascularization and GluR-1 expression in rats. Nutr Neurosci 2021; 25:2517-2527. [PMID: 34565308 DOI: 10.1080/1028415x.2021.1980845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Cyclic glycine-proline (cGP) is a natural nutrient of breast milk and plays a role in regulating the function of insulin-like growth factor-1 (IGF-1). IGF-1 function is essential for post-natal brain development and adult cognitive function. We evaluated the effects of cGP on spatial memory and histological changes in the hippocampus of the adult rats following infancy administration. Infant rats were treated with either cGP or saline between post-natal days 8 and 22 via oral administration to lactating dams. The spatial memory was evaluated between post-natal days 70 and 75 using Morris water maze tests. The changes of capillaries, astrocytes, synaptophysin and glutamate receptor-1 were examined in the CA1 stratum radiatum of the hippocampus. Compared to saline-treated group, cGP-treated group showed higher path efficiency of entry and lower average heading errors to the platform zone. cGP-treated group also showed longer, larger and more astrocytic processes, more capillaries and higher glutamate receptor-1 expression. The rats made less average heading error to the platform zone have more capillaries, larger and longer astrocytic branches. Thus cGP treatment/supplementation during infancy moderately improved adulthood spatial memory. This long-lasting effect of cGP on memory could be mediated via promoting astrocytic plasticity, vascularization and glutamate trafficking. Therefore, cGP may have a role in regulating IGF-1 function during brain development.
Collapse
Affiliation(s)
- Gagandeep Singh-Mallah
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.,AgResearch Ltd., Ruakura Research Centre, Hamilton, New Zealand.,Gravida, National Centre for Growth and Development, Liggins Institute, University of Auckland, Auckland, New Zealand.,Liggins Institute, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.,Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.,Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - Maryam Ardalan
- Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - Dali Kang
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Kuljeet Singh
- AgResearch Ltd., Ruakura Research Centre, Hamilton, New Zealand.,Gravida, National Centre for Growth and Development, Liggins Institute, University of Auckland, Auckland, New Zealand
| | - Christopher D McMahon
- AgResearch Ltd., Ruakura Research Centre, Hamilton, New Zealand.,Gravida, National Centre for Growth and Development, Liggins Institute, University of Auckland, Auckland, New Zealand
| | - Carina Mallard
- Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - Jian Guan
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.,Gravida, National Centre for Growth and Development, Liggins Institute, University of Auckland, Auckland, New Zealand.,Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| |
Collapse
|
7
|
Kang D, Waldvogel HJ, Wang A, Fan D, Faull RLM, Curtis MA, Shorten PR, Guan J. The autocrine regulation of insulin-like growth factor-1 in human brain of Alzheimer's disease. Psychoneuroendocrinology 2021; 127:105191. [PMID: 33706042 DOI: 10.1016/j.psyneuen.2021.105191] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 03/02/2021] [Accepted: 03/03/2021] [Indexed: 12/31/2022]
Abstract
BACKGROUND Insulin-like growth factor (IGF) binding protein (IGFBP)-3 and cyclic Glycine-Proline (cGP) regulate circulating IGF-1 function that is associated with cognition. The association between IGF-1 function and Alzheimer's disease (AD) remains inconclusive. This study evaluated the changes of IGFBPs and cGP, and their effects on the bioavailability and function of IGF-1 in human brain of AD cases. METHODS Using biological and mathematic analysis we measured the concentrations of total, bound and unbound forms of IGF-1, IGFBPs and cGP in the inferior-frontal gyrus and middle-frontal gyrus of human AD (n = 15) and control cases (n = 15). The association between the changes of total concentration of these peptides and total protein concentration in brain tissues were also analyzed. RESULTS The unbound bioavailable IGF-1 was lower whereas the bound cGP and IGFBP-3 were higher in AD than the control cases. Total protein that was lower in AD than control cases, was negatively associated with cGP concentration of control cases and with IGFBP-3 concentration of AD cases. CONCLUSIONS The results provide direct evidence for IGF-1 deficiency in AD brain due to lower bioavailable IGF-1. The increase of bound IGFBP-3 impaired autocrine regulation. The increase of bound cGP is an autocrine response to improve the bioavailability and function of IGF-1 in AD brain. AVAILABILITY OF DATA AND MATERIAL All data generated or analysed during this study are included in this published article. Additional datasets analysed during the current study available from the corresponding author on reasonable request.
Collapse
Affiliation(s)
- Dali Kang
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Science, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand
| | - Henry J Waldvogel
- Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Science, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand; Department of Anatomy and Medical Imaging, Faculty of Medicine and Health Science, University of Auckland, New Zealand
| | - Ao Wang
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Science, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand
| | - Dawei Fan
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Science, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand
| | - Richard L M Faull
- Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Science, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand; Department of Anatomy and Medical Imaging, Faculty of Medicine and Health Science, University of Auckland, New Zealand
| | - Maurice A Curtis
- Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Science, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand; Department of Anatomy and Medical Imaging, Faculty of Medicine and Health Science, University of Auckland, New Zealand
| | - Paul R Shorten
- AgResearch Ltd, Ruakura Research Centre, Hamilton 3240, New Zealand; Riddet Institute, Massey University, Palmerston North 4442, New Zealand
| | - Jian Guan
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Science, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand.
| |
Collapse
|
8
|
Fan D, Pitcher T, Dalrymple‐Alford J, MacAskill M, Anderson T, Guan J. Changes of plasma cGP/IGF-1 molar ratio with age is associated with cognitive status of Parkinson disease. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2020; 12:e12025. [PMID: 32671179 PMCID: PMC7346731 DOI: 10.1002/dad2.12025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/08/2019] [Revised: 01/09/2020] [Accepted: 01/23/2020] [Indexed: 12/19/2022]
Abstract
OBJECTIVE Cognitive impairment is a common feature of Parkinson disease (PD), for which age is a major contributing factor. Insulin-like growth factor-1 (IGF-1) declines with age and contributes to age-related cognitive impairment in PD. Cyclic glycine-proline (cGP) is a metabolite of IGF-1 and normalizes bioavailable IGF-1. Plasma cGP/IGF-1 molar ratio that represents bioactive IGF-1 in circulation, may associate with the cognitive status in PD. METHODS We examined the association of plasma cGP/IGF-1 molar ratio with the cognitive scores or age in PD patients with normal cognition (PD-N, n = 74), mild cognitive impairment (PD-MCI, n = 71), or dementia (PD-D, n = 33), and with the cognitive scores in 23 age-matched healthy controls. Plasma concentrations of IGF-1, IGF binding protein-3, and cGP were evaluated using enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography-mass spectrometry (HPLC-MS), respectively. RESULTS The cGP/IGF-1 molar ratio was positively correlated with the age of PD-N group, negatively correlated with the age of PD-D group, and not associated with the age of PD-MCI group. Independent of age, the cGP/IGF-1 molar ratio was positively correlated with the cognitive scores of healthy controls, but not in PD groups. CONCLUSION Old healthy people with a higher cGP/IGF-1 molar ratio showed better preserved cognition, possibly due to improved IGF-1 function. Increased cGP/IGF-1 molar ratio with age may contribute to cognitive retention in the PD-N group. The absence or reversal of such association with age in the PD-MCI and PD-D groups may indicate the conversion of cognitive status in PD, if confirmed through longitudinal investigations within the individuals with advancing cognitive impairment.
Collapse
Affiliation(s)
- Dawei Fan
- Department of Pharmacology and Clinical PharmacologySchool of Medical SciencesFaculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand
- Centre for Brain ResearchSchool of Medical SciencesFaculty of Medical and Health ScienceUniversity of AucklandAucklandNew Zealand
- Brain Research New Zealand, A Centre of Research ExcellenceAucklandNew Zealand
| | - Toni Pitcher
- Brain Research New Zealand, A Centre of Research ExcellenceAucklandNew Zealand
- New Zealand Brain Research InstituteChristchurchNew Zealand
- Department of MedicineUniversity of OtagoDunedinNew Zealand
| | - John Dalrymple‐Alford
- Brain Research New Zealand, A Centre of Research ExcellenceAucklandNew Zealand
- New Zealand Brain Research InstituteChristchurchNew Zealand
- Department of PsychologyUniversity of CanterburyChristchurchNew Zealand
| | - Michael MacAskill
- New Zealand Brain Research InstituteChristchurchNew Zealand
- Department of MedicineUniversity of OtagoDunedinNew Zealand
| | - Tim Anderson
- Brain Research New Zealand, A Centre of Research ExcellenceAucklandNew Zealand
- New Zealand Brain Research InstituteChristchurchNew Zealand
- Department of MedicineUniversity of OtagoDunedinNew Zealand
- Department of NeurologyCanterbury District Health BoardChristchurchNew Zealand
| | - Jian Guan
- Department of Pharmacology and Clinical PharmacologySchool of Medical SciencesFaculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand
- Centre for Brain ResearchSchool of Medical SciencesFaculty of Medical and Health ScienceUniversity of AucklandAucklandNew Zealand
- Brain Research New Zealand, A Centre of Research ExcellenceAucklandNew Zealand
| |
Collapse
|
9
|
Li F, Liu K, Gray C, Harris P, Reynolds CM, Vickers MH, Guan J. Cyclic glycine-proline normalizes systolic blood pressure in high-fat diet-induced obese male rats. Nutr Metab Cardiovasc Dis 2020; 30:339-346. [PMID: 31753784 DOI: 10.1016/j.numecd.2019.09.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2019] [Revised: 09/13/2019] [Accepted: 09/17/2019] [Indexed: 12/30/2022]
Abstract
BACKGROUND AND AIMS Insulin-like growth factor (IGF)-1 deficiency is associated with a range of metabolic disorders. Cyclic glycine-proline (cGP) is a natural nutrient and regulates the amount of active IGF-1 in plasma. Plasma cGP decreases in hypertensive women whereas increases in obese women, suggesting its involvement in cardio-metabolic function. We therefore examined the effects of cGP on metabolic profiles and blood pressure in high-fat diet (HFD)-induced obese male rats. METHODS Male rats were fed either a HFD or a standard chow diet (STD) ad-libitum from 3 to 15 weeks of age. Rats were administered either saline or cGP from 11 to 15 weeks of age. At 14 weeks of age, systolic-blood pressure (SBP) was measured by tail-cuff plethysmography and body composition quantified by DEXA. Blood and retroperitoneal fat tissues were collected. Plasma concentrations of insulin, IGF-1, IGF binding protein (IGFBP)-3 and cGP were evaluated using ELISA and HPLC-MS respectively. RESULTS Compared to STD, HFD feeding increased SBP, total fat mass and fat/lean ratio, retroperitoneal fat weight, fasting plasma insulin and cGP concentrations whereas decreased plasma IGF-1 and IGFBP-3 concentrations. Administration of cGP reduced SBP and retroperitoneal fat weight, but had no effect on body composition and plasma insulin concentrations. CONCLUSION HFD-associated decreases in IGFBP-3 and increases in cGP represent an autocrine response to normalize IGF-1 function through improving the amount of bioavailable IGF-1 in the circulation of obese male rats. The beneficial effects of cGP on SBP and retroperitoneal fat mass may suggest a therapeutic potential for cGP in HFD-associated cardio-metabolic complications.
Collapse
Affiliation(s)
- Fengxia Li
- The Seventh Affiliated Hospital, Sun Yat-sen University, 628 Zhenyuan Road, Guangming District, Shenzhen, 518107, China; Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou, 510000, China; Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangzhou Higher Education Mega Center, 280 Waihuangdong Road, Guangzhou, 510008, China; The Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1142, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1142, New Zealand
| | - Karen Liu
- The Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1142, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1142, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand
| | - Clint Gray
- The Liggins Institute, University of Auckland, 85 Park Road, Grafton, Auckland, 1142, New Zealand
| | - Paul Harris
- Department of Medicinal Chemistry, School of Chemistry, Faculty of Science, University of Auckland, 1142, New Zealand
| | - Clare M Reynolds
- The Liggins Institute, University of Auckland, 85 Park Road, Grafton, Auckland, 1142, New Zealand
| | - Mark H Vickers
- The Liggins Institute, University of Auckland, 85 Park Road, Grafton, Auckland, 1142, New Zealand
| | - Jian Guan
- The Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1142, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1142, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand.
| |
Collapse
|
10
|
The role of oligopeptides in preventing autism. Med Hypotheses 2020; 138:109604. [PMID: 32018147 DOI: 10.1016/j.mehy.2020.109604] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2019] [Revised: 01/21/2020] [Accepted: 01/24/2020] [Indexed: 01/18/2023]
Abstract
Previous reports in this series point to insufficient insulin-like growth factor-1 (IGF1) in the newborn as the key to brain dysconnectivity characteristic of autism. Such a deficiency should be detectable in the baby's blood at or soon after birth. Breast-feeding exclusively for the first year of postpartum life or supplementation with oral agents to raise the serum IGF1 level, such a cyclo-glycylproline, could be helpful for this purpose.
Collapse
|
11
|
Sexually Dimorphic Associations between Maternal Factors and Human Milk Hormonal Concentrations. Nutrients 2020; 12:nu12010152. [PMID: 31935821 PMCID: PMC7019968 DOI: 10.3390/nu12010152] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 12/22/2019] [Accepted: 12/31/2019] [Indexed: 12/28/2022] Open
Abstract
While human milk composition is characterised by marked dynamicity, we are far from having a clear picture of what factors drive this variation. Hormones in human milk are known to vary according to specific maternal phenotypes, but limited evidence shows the infant also has a role in determining milk composition. The present study aimed to investigate the interplay between maternal and infant characteristics in relation to human milk hormonal profile. In total, 501 human milk samples from mothers recruited in the Finnish STEPS cohort study (Steps to the healthy development) were analysed. Pre-pregnancy and pregnancy maternal data, socioeconomic status and infant characteristics at birth were collated. Leptin, adiponectin, insulin-like growth factor-1 and cyclic Glycine-Proline in milk were measured. Multivariate analysis of variance (MANOVA) and linear regression were utilised for statistical analysis. Sex-specific interactions with maternal factors were observed, as the infant sex mediated associations between gestational diabetes and milk adiponectin (p = 0.031), birth-mode and total protein (p = 0.003), maternal education and insulin-like growth factor-1: cyclic Glycine-Proline ratio (p = 0.035). Our results suggest that changes in human milk composition are associated with interactions between maternal and infant characteristics and pathophysiological factors. Future work should expand on these findings and further explore the link between hormonal profiles in human milk and infant outcomes.
Collapse
|
12
|
Misiura M, Miltyk W. Proline-containing peptides-New insight and implications: A Review. Biofactors 2019; 45:857-866. [PMID: 31430415 DOI: 10.1002/biof.1554] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Revised: 07/15/2019] [Accepted: 07/31/2019] [Indexed: 12/18/2022]
Abstract
The family of regulatory proline-containing peptides (PCPs), also known as glyprolines, exhibit significant biological activity. The group of glyprolines includes Gly-Pro (GP), Pro-Gly-Pro (PGP), cyclic Gly-Pro (cGP), as well as PGP derivatives, for example, N-acetylated PGP (N-a-PGP) and N-methylated PGP (N-m-PGP). PCPs are engaged in various biological processes including the proinflammatory neutrophil chemoattraction in lung diseases, inflammatory bowel diseases or ischemic stroke. Glyprolines have been also postulated to play an important role as atheroprotective and anticoagulant agents, exhibit neuroprotective effects in Parkinson's disease, as well as regulate insulin-like growth factor (IGF) homeostasis. It was also noticed that PCPs inhibit proliferation and migration of keratinocytes in wound healing, protection of the gastric mucosa and stimulation of its regeneration. The regulatory glyprolines are derived from endogenous and exogenous sources. Most PCPs are derived from collagen or diet protein degradation. Recently, great interest is concentrated on short proline-rich oligopeptides derived from IGF-1 degradation. The mechanism of PCPs biological activity is not fully explained. It involves receptor-mediated mechanisms, for example, N-a-PGP acts as CXCR1/2 receptor ligand, whereas cGP regulates IGF-1 bioavailability by modifying the IGF-1 binding to the IGF-1 binding protein-3. PGP has been observed to interact with collagen-specific receptors. The data suggest a promising role of PGP as a target of various diseases therapy. This review is focused on the effect of PCPs on metabolic processes in different tissues and the molecular mechanism of their action as an approach to pharmacotherapy of PCPs-dependent diseases.
Collapse
Affiliation(s)
- Magdalena Misiura
- Department of Pharmaceutical Analysis and Bioanalysis, Medical University of Bialystok, Białystok, Poland
| | - Wojciech Miltyk
- Department of Pharmaceutical Analysis and Bioanalysis, Medical University of Bialystok, Białystok, Poland
| |
Collapse
|
13
|
Li F, Liu K, Wang A, Harris PWR, Vickers MH, Guan J. Cyclic glycine-proline administration normalizes high-fat diet-induced synaptophysin expression in obese rats. Neuropeptides 2019; 76:101935. [PMID: 31146894 DOI: 10.1016/j.npep.2019.05.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 04/15/2019] [Accepted: 05/21/2019] [Indexed: 01/06/2023]
Abstract
Childhood metabolic disorders are associated with insulin-like growth factor (IGF)-1 deficiency, which can adversely affect brain development and function. As a neuropeptide, cyclic glycine-proline (cGP) improves IGF-1 function in brain and regulates IGF-1 bioavailability in plasma. Whether such a regulatory process mediates the neurotrophic effects of cGP remains unknown. This study examined the effects cGP treatment on synaptic expression and their association with IGF-1, IGF binding protein (IGFBP)-2 and cGP concentrations in the brain of rats with high fat diet (HFD)-induced obesity. Male rats received either a HFD or a standard chow diet (STD) from weaning and were then treated with either saline or cGP from 11 to 15 weeks of age. The concentrations of cGP, IGF-1 and IGFBP-2 were measured in the brain tissues using ELISA and HPLC-MS. The expressions of synaptic markers were evaluated in the hippocampus, hypothalamus and striatum using immunohistochemical staining. Compared to the STD group, IGF-1 and IGFBP-2, but not cGP concentrations, were lower in the HFD groups. The expression of hippocampal synaptophysin, glutamate receptor-1, GFAP and striatal tyrosine-hydroxylase were also reduced in the HFD groups. While treatment did not alter tissue IGF-1, cGP administration that increased the concentration of cGP in brain tissues, normalized the expression of synaptophysin, GFAP and tyrosine-hydroxylase, but not glutamate receptor-1. IGF-1 concentration in brain tissues correlated with the expression of all synaptic markers. HFD feeding reduced synaptic expression and tissue IGF-1 in brains which were closely associated, thus suggesting IGF-1 in the brain is largely bioavailable. Without increasing IGF-1 in the brain, administration of cGP normalized synaptic expression, possibly be mediated through increasing bioavailable IGF-1, but further studies are required to confirm this.
Collapse
Affiliation(s)
- Fengxia Li
- Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China; Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangzhou, China; The Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1124, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand
| | - Karen Liu
- The Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1124, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand
| | - Ao Wang
- The Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1124, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand
| | - Paul W R Harris
- School of Chemical Sciences, Faculty of Science, University of Auckland, New Zealand
| | - Mark H Vickers
- The Liggins Institute, University of Auckland, New Zealand
| | - Jian Guan
- The Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand; Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1124, New Zealand; Brain Research New Zealand, A Centre of Research Excellence, New Zealand.
| |
Collapse
|
14
|
Fan D, Krishnamurthi R, Harris P, Barber PA, Guan J. Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients. Ann Clin Transl Neurol 2019; 6:669-677. [PMID: 31019991 PMCID: PMC6469247 DOI: 10.1002/acn3.743] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Revised: 01/28/2019] [Accepted: 02/01/2019] [Indexed: 12/14/2022] Open
Abstract
Objective Many stroke patients make a partial recovery in function during the first 3 months, partially through promoting insulin‐like growth factor‐1 (IGF‐1) function. A prognostic biomarker that associates with IGF‐1 function may predict clinical outcome and recovery of stroke. This study evaluated plasma concentrations of IGF‐1, IGF binding protein (IGFBP)‐3 and cyclic‐glycine‐proline (cGP) and their associations with clinical outcome in stroke patients. Methods Thirty‐four patients were recruited within 3 days of stroke. Clinical assessments included the National Institutes of Health Stroke Scale (NIHSS) within 3 days (baseline), and at days 7 and 90; the modified Rankin Scale (mRS) and Fugl‐Meyer Upper‐Limb Assessment Scale (FM‐UL) at days 7 and 90. Plasma samples were collected from the patients at the baseline, days 7 and 90. Fifty age‐matched control participants with no history of stroke were also recruited and provided plasma samples. IGF‐1, IGFBP‐3, and cGP concentrations were analyzed using ELISA or HPLC‐MS. Results Baseline concentrations of IGFBP‐3, cGP, and cGP/IGF‐1 ratio were lower in stroke patients than the control group. The neurological scores of stroke patients were improved and plasma cGP and cGP/IGF‐1 ratio increased over time. Baseline cGP/IGF‐1 ratio was correlated with the NIHSS scores at day 90 and the changes in NIHSS scores from the baseline to 90 days. Interpretation Low cGP concentrations and cGP/IGF‐1 ratio in stroke patients suggest an impaired IGF‐1 function. The cGP/IGF‐1 ratio at admission maybe further developed as a prognostic biomarker for stroke recovery.
Collapse
Affiliation(s)
- Dawei Fan
- Department of Pharmacology and Clinical Pharmacology School of Medical Sciences Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.,Centre for Brain Research School of Medical Sciences Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.,Brain Research New Zealand - A Centre of Research Excellence Auckland New Zealand
| | - Rita Krishnamurthi
- Brain Research New Zealand - A Centre of Research Excellence Auckland New Zealand.,National Institute for Stroke and Applied Neurosciences Auckland University of Technology Auckland New Zealand
| | - Paul Harris
- School of Chemical Sciences School of Biological Sciences University of Auckland Auckland New Zealand
| | - P Alan Barber
- Centre for Brain Research School of Medical Sciences Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.,Brain Research New Zealand - A Centre of Research Excellence Auckland New Zealand.,Department of Neurology School of Medicine University of Auckland Auckland New Zealand
| | - Jian Guan
- Department of Pharmacology and Clinical Pharmacology School of Medical Sciences Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.,Centre for Brain Research School of Medical Sciences Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand.,Brain Research New Zealand - A Centre of Research Excellence Auckland New Zealand
| |
Collapse
|
15
|
Dobolyi A, Lékó AH. The insulin-like growth factor-1 system in the adult mammalian brain and its implications in central maternal adaptation. Front Neuroendocrinol 2019; 52:181-194. [PMID: 30552909 DOI: 10.1016/j.yfrne.2018.12.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 11/04/2018] [Accepted: 12/11/2018] [Indexed: 12/15/2022]
Abstract
Our knowledge on the bioavailability and actions of insulin-like growth factor-1 (IGF-1) has markedly expanded in recent years as novel mechanisms were discovered on IGF binding proteins (IGFBPs) and their ability to release IGF-1. The new discoveries allowed a better understanding of the endogenous physiological actions of IGF-1 and also its applicability in therapeutics. The focus of the present review is to summarize novel findings on the neuronal, neuroendocrine and neuroplastic actions of IGF-1 in the adult brain. As most of the new regulatory mechanisms were described in the periphery, their implications on brain IGF system will also be covered. In addition, novel findings on the effects of IGF-1 on lactation and maternal behavior are described. Based on the enormous neuroplastic changes related to the peripartum period, IGF-1 has great but largely unexplored potential in maternal adaptation of the brain, which is highlighted in the present review.
Collapse
Affiliation(s)
- Arpád Dobolyi
- MTA-ELTE Laboratory of Molecular and Systems Neurobiology, Department of Physiology and Neurobiology, Hungarian Academy of Sciences and Eötvös Loránd University, Budapest, Hungary.
| | - András H Lékó
- MTA-ELTE Laboratory of Molecular and Systems Neurobiology, Department of Physiology and Neurobiology, Hungarian Academy of Sciences and Eötvös Loránd University, Budapest, Hungary; Laboratory of Neuromorphology, Department of Anatomy, Histology and Embryology, Semmelweis University, Budapest, Hungary; Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
| |
Collapse
|
16
|
Steinman G. IGF – Autism prevention/amelioration. Med Hypotheses 2019; 122:45-47. [DOI: 10.1016/j.mehy.2018.10.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Revised: 10/16/2018] [Accepted: 10/20/2018] [Indexed: 01/19/2023]
|
17
|
Abstract
(1) This study describes the good evolution of a 6-year-old girl genetically diagnosed (R106X) with Rett syndrome (RTT), after having been treated with IGF-I, melatonin (MT), blackcurrant extracts (BC) and rehabilitated for 6 months. (2) The patient stopped normal development in the first year of age. The patient showed short stature and weight and fulfilled the main criteria for typical RTT. Despite her young age, there was pubic hair (Tanner II), very high plasma testosterone, and low levels of plasma gonadotrophins. There were no adrenal enzymatic deficits, and abdominal ultrasound studies were normal. The treatment consisted of IGF-I (0.04 mg/kg/day, 5 days/week, subcutaneous (sc)) for 3 months and then 15 days of rest, MT (50 mg/day, orally, without interruption) and neurorehabilitation. A new blood test, after 3 months of treatment, was absolutely normal and the pubic hair disappeared (Tanner I). Then, a new treatment was started with IGF-I, MT, and BC for another 3 months. In this period, the degree of pubertal development increased to Tanner III (pubic level), without a known cause. (3) The treatment followed led to clear improvements in most of the initial abnormalities, perhaps due to the neurotrophic effect of IGF-I, the antioxidant effects of MT and BC, and the cerebral increase in the cyclic glycine-proline (cGP) achieved with administration of BC. (4) A continuous treatment with IGF-I, MT, and BC appears to be useful in RTT.
Collapse
|
18
|
Fan D, Alamri Y, Liu K, MacAskill M, Harris P, Brimble M, Dalrymple-Alford J, Prickett T, Menzies O, Laurenson A, Anderson T, Guan J. Supplementation of Blackcurrant Anthocyanins Increased Cyclic Glycine-Proline in the Cerebrospinal Fluid of Parkinson Patients: Potential Treatment to Improve Insulin-Like Growth Factor-1 Function. Nutrients 2018; 10:nu10060714. [PMID: 29865234 PMCID: PMC6024688 DOI: 10.3390/nu10060714] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Revised: 05/30/2018] [Accepted: 05/31/2018] [Indexed: 01/04/2023] Open
Abstract
Background: Insulin-like growth factor-1 (IGF-1) function is impaired in Parkinson disease. Cyclic glycine-proline (cGP), a metabolite of IGF-1, is neuroprotective through improving IGF-1 function. Parkinson disease patients score lower on Hospital-associated Anxiety and Depression Scale after supplementing blackcurrant anthocyanins (BCA), which may be associated with IGF-1 function. We evaluated the changes of cGP and IGF-1 before and after the supplementation. Methods: Plasma and cerebrospinal fluid (CSF) were collected from 11 male patients before and after 28 day supplementation of BCA. The concentrations of IGF-1, IGF binding protein (IGFBP)-3, and cGP were measured using ELISA and HPLC-MS assays. The presence of cGP in the BCA was evaluated. Results: cGP presented in the BCA. BCA supplementation increased the concentration of cGP (p < 0.01), but not IGF-1 and IGFBP-3 in the CSF. CSF concentration of cGP was correlated with plasma concentration of cGP (R = 0.68, p = 0.01) and cGP/IGF-1 molar ratio (R = 0.66, p = 0.01). The CSF/plasma ratio was high in cGP and low in IGF-1 and IGFBP-3. Conclusion: cGP is a natural nutrient to the BCA. The increased CSF cGP in Parkinson disease patients may result from the central uptake of plasma cGP. Given neurotrophic function, oral availability, and effective central uptake of cGP, the BCA has the potential to be developed to treat neurological conditions with IGF-1 deficiency.
Collapse
Affiliation(s)
- Dawei Fan
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand.
- Centre for Brain Research, Faculty of Medicine and Health Science, University of Auckland, Auckland 1142, New Zealand.
- Brain Research New Zealand, A Centre of Research Excellence, New Zealand.
| | - Yassar Alamri
- New Zealand Brain Research Institute, Christchurch 8011, New Zealand.
- Canterbury District Health Board, Christchurch 8041, New Zealand.
- Department of Medicine, University of Otago, Dunedin 9016, New Zealand.
| | - Karen Liu
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand.
- Centre for Brain Research, Faculty of Medicine and Health Science, University of Auckland, Auckland 1142, New Zealand.
- Brain Research New Zealand, A Centre of Research Excellence, New Zealand.
| | - Michael MacAskill
- New Zealand Brain Research Institute, Christchurch 8011, New Zealand.
| | - Paul Harris
- Department of Medicinal Chemistry, School of Chemistry, University of Auckland, Auckland 1142, New Zealand.
| | - Margaret Brimble
- Brain Research New Zealand, A Centre of Research Excellence, New Zealand.
- Department of Medicinal Chemistry, School of Chemistry, University of Auckland, Auckland 1142, New Zealand.
| | - John Dalrymple-Alford
- Brain Research New Zealand, A Centre of Research Excellence, New Zealand.
- New Zealand Brain Research Institute, Christchurch 8011, New Zealand.
- Department of Psychology, University of Canterbury, Christchurch 8041, New Zealand.
| | - Tim Prickett
- Department of Medicine, University of Otago, Dunedin 9016, New Zealand.
| | - Oliver Menzies
- Department of Geriatric Medicine, Auckland District Health Board, Auckland, 1142, New Zealand.
| | - Andrew Laurenson
- Canterbury District Health Board, Christchurch 8041, New Zealand.
| | - Tim Anderson
- Centre for Brain Research, Faculty of Medicine and Health Science, University of Auckland, Auckland 1142, New Zealand.
- Brain Research New Zealand, A Centre of Research Excellence, New Zealand.
- New Zealand Brain Research Institute, Christchurch 8011, New Zealand.
- Canterbury District Health Board, Christchurch 8041, New Zealand.
- Department of Medicine, University of Otago, Dunedin 9016, New Zealand.
- Department of Neurology, Christchurch Public Hospital, Christchurch 8140, New Zealand.
| | - Jian Guan
- Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand.
- Centre for Brain Research, Faculty of Medicine and Health Science, University of Auckland, Auckland 1142, New Zealand.
- Brain Research New Zealand, A Centre of Research Excellence, New Zealand.
| |
Collapse
|
19
|
Singh-Mallah G, McMahon CD, Guan J, Singh K. Cyclic-glycine-proline accelerates mammary involution by promoting apoptosis and inhibiting IGF-1 function. J Cell Physiol 2017; 232:3369-3383. [PMID: 28063218 DOI: 10.1002/jcp.25782] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Revised: 01/04/2017] [Accepted: 01/05/2017] [Indexed: 12/15/2022]
Abstract
In rodents, post-lactational involution of mammary glands is characterized by the loss of mammary epithelial cells via apoptosis, which is associated with a decline in the expression of insulin-like growth factor-1 (IGF-1). Overexpression of IGF-1 delays involution by inhibiting apoptosis of epithelial cells and preserving the remaining secretory alveoli. Cyclic-glycine-proline (cGP), a metabolite of IGF-1, normalizes IGF-1 function under pathological conditions by regulating the bioavailability of IGF-1. The present study investigated the effect of cGP on the physiological decline in IGF-1 function during post-lactational mammary involution. Rat dams were gavaged with either cGP (3 mg/kg) or saline once per day from post-natal d8-22. Before collecting tissue on post-natal d23, a pair of mammary glands were sealed on d20 (72 hr-engorgement, thus representative of late-involution) and d22 (24 hr-engorgement, thus representative of mid-involution), while the remaining glands were allowed to involute naturally (early-involution). During early-involution, cGP accelerated the loss of mammary cells through apoptosis, resulting in an earlier clearance of intact secretory alveoli compared with the control group. This coincided with an earlier up-regulation of the cell survival factors, Bcl-xl and IGF-1R, in the early-involution cGP glands compared with the control glands. During late-involution, cGP reduced the bioactivity of IGF-1, which was evident through decreased phosphorylation of IGF-1R in the regressed alveoli. Maternal administration of cGP did not alter milk production and composition during early-, peak-, or late-stage of lactation. These data show that cGP accelerates post-lactational involution by promoting apoptosis and the physiological decline in IGF-1 function.
Collapse
Affiliation(s)
- Gagandeep Singh-Mallah
- Liggins Institute, University of Auckland, Auckland, New Zealand.,AgResearch Ltd., Ruakura Research Centre, Hamilton, New Zealand.,Gravida, National Centre for Growth and Development, Liggins Institute, University of Auckland, Auckland, New Zealand.,Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Christopher D McMahon
- AgResearch Ltd., Ruakura Research Centre, Hamilton, New Zealand.,Gravida, National Centre for Growth and Development, Liggins Institute, University of Auckland, Auckland, New Zealand
| | - Jian Guan
- Gravida, National Centre for Growth and Development, Liggins Institute, University of Auckland, Auckland, New Zealand.,Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.,Brain Research New Zealand, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.,Faculty of Medical and Health Sciences, Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, University of Auckland, Auckland, New Zealand
| | - Kuljeet Singh
- AgResearch Ltd., Ruakura Research Centre, Hamilton, New Zealand.,Gravida, National Centre for Growth and Development, Liggins Institute, University of Auckland, Auckland, New Zealand
| |
Collapse
|